BioCentury
ARTICLE | Company News

TG, Novimmune developing CD47/CD19 bispecific

June 20, 2018 8:02 PM UTC

TG Therapeutics Inc. (NASDAQ:TGTX) partnered with Novimmune S.A. (Plan-les-Ouates, Switzerland) to develop Novimmune’s TG-1801 (formerly NI-1701). The companies plan to begin clinical testing of the candidate this year or early next year, with a focus on hematologic B cell malignancies.

The kappa-lambda antibody is a human bispecific IgG targeting CD47 and CD19. TG and Novimmune said they expect it to be the world’s first anti-CD47 bispecific antibody to enter the clinic...

BCIQ Target Profiles

CD19

CD47